BEZ235 plus everolimus (RAD001)
Phase 2Small molecule
BEZ235 plus everolimus (RAD001) is one of 13 small molecule programs targeting Respiratory tract infection. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Respiratory Tract Infection
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Advil
KKenvue Brands
Approved
Tylenol
KKenvue Brands
Approved
Tobrex
VViatris Specialty LLC
Approved
Levaquin
WWim Janssens
Approved
Merrem
BB. Braun Medical Inc.
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Biaxin
AbbViePreclinical
BEYFORTUS
SanofiPreclinical
BEZ235
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRestorbio Inc.